DAWN — Day One Biopharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m-27.74%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-36.72%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Day One Biopharmaceuticals EPS forecast chart

Profile Summary

Day One Biopharmaceuticals, Inc., formerly Day One Biopharmaceuticals Holding Company, LLC, is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. It focuses on clinical development on pediatric patients living with cancer. The Company's lead product candidate, DAY101, is an oral, brain-penetrant, selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
January 1st, 1970
Public Since
January 1st, 1970
No. of Employees
42
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
61,928,939

DAWN Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email